Labcorp Holdings Inc.(NYSE) LH

Labcorp Holdings Inc. helps doctors identify illnesses through medical tests. It gives patients clear facts to make health choices. The company also assists drug firms with scientific research.

Everyday Diagnostic Tools

• Diagnostics: Medical laboratory testing services provided to healthcare providers; revenues reached $2.9 billion for the three months ended June 30, 2026.
• Biopharma Laboratory Services: Clinical trial support and research for drug developers; revenues were $836.2 million for the three months ended June 30, 2026.
• Central Laboratory: Specialized testing services used by scientific investigators to conduct medical trials.

Building the Health Network

• Completed the spin-off of Fortrea, its former clinical development and commercialization business.
• Entered an agreement on June 28, 2026, to acquire select outreach laboratory assets for $155.0 million.
• Secured a $750.0 million term loan in March 2026 to redeem outstanding senior notes.
• Amended an accounts receivable facility on Jan. 28, 2026, to extend its term to 2029.

Precision and Scale

Labcorp operates a network of testing facilities and patient service centers to collect and analyze medical specimens. The company uses its LaunchPad initiative and automation platforms to streamline operations and improve diagnostic accuracy.

Vital Financial Facts

• Total revenue reached $3.7 billion for the three months ended June 30, 2026, up 5.8% year over year.
• Operating income was $451.6 million for the three months ended June 30, 2026, a 14.5% increase.
• Net cash from operating activities totaled $637.0 million for the six months ended June 30, 2026.
• Cash and cash equivalents were $141.8 million as of June 30, 2026.

Bottom Line

Labcorp has evolved by narrowing its focus to high-growth diagnostic and biopharma services through strategic divestitures. Ongoing investments in laboratory technology and outreach acquisitions help the company maintain its scale in healthcare testing.